ATE122238T1 - Bifunktionelle antikörperkonstruktionen und verfahren zur selektiven tötung von zellbeständen. - Google Patents
Bifunktionelle antikörperkonstruktionen und verfahren zur selektiven tötung von zellbeständen.Info
- Publication number
- ATE122238T1 ATE122238T1 AT88108793T AT88108793T ATE122238T1 AT E122238 T1 ATE122238 T1 AT E122238T1 AT 88108793 T AT88108793 T AT 88108793T AT 88108793 T AT88108793 T AT 88108793T AT E122238 T1 ATE122238 T1 AT E122238T1
- Authority
- AT
- Austria
- Prior art keywords
- component
- antibody
- lymphocyte
- bifunctional
- binding
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6875—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody being a hybrid immunoglobulin
- A61K47/6879—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody being a hybrid immunoglobulin the immunoglobulin having two or more different antigen-binding sites, e.g. bispecific or multispecific immunoglobulin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biochemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US6020587A | 1987-06-10 | 1987-06-10 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE122238T1 true ATE122238T1 (de) | 1995-05-15 |
Family
ID=22028021
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT88108793T ATE122238T1 (de) | 1987-06-10 | 1988-06-01 | Bifunktionelle antikörperkonstruktionen und verfahren zur selektiven tötung von zellbeständen. |
Country Status (4)
| Country | Link |
|---|---|
| EP (1) | EP0294703B1 (de) |
| AT (1) | ATE122238T1 (de) |
| DE (1) | DE3853740T2 (de) |
| ES (1) | ES2073394T3 (de) |
Families Citing this family (50)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5869620A (en) * | 1986-09-02 | 1999-02-09 | Enzon, Inc. | Multivalent antigen-binding proteins |
| WO1989006544A1 (en) * | 1988-01-15 | 1989-07-27 | Centocor, Inc. | Heteroligating antibodies and therapeutic uses thereof |
| US4925648A (en) * | 1988-07-29 | 1990-05-15 | Immunomedics, Inc. | Detection and treatment of infectious and inflammatory lesions |
| US5225538A (en) * | 1989-02-23 | 1993-07-06 | Genentech, Inc. | Lymphocyte homing receptor/immunoglobulin fusion proteins |
| US5173293A (en) * | 1989-02-23 | 1992-12-22 | Becton Dickinson And Company | Anti-T-cell antibodies as adjuvants |
| US6406697B1 (en) | 1989-02-23 | 2002-06-18 | Genentech, Inc. | Hybrid immunoglobulins |
| US5116964A (en) * | 1989-02-23 | 1992-05-26 | Genentech, Inc. | Hybrid immunoglobulins |
| FR2649119A1 (fr) * | 1989-06-30 | 1991-01-04 | Centre Nat Rech Scient | Procede de pilotage de retrovirus en utilisant des complexes bifonctionnels |
| AU6290090A (en) * | 1989-08-29 | 1991-04-08 | University Of Southampton | Bi-or trispecific (fab)3 or (fab)4 conjugates |
| US5650150A (en) * | 1990-11-09 | 1997-07-22 | Gillies; Stephen D. | Recombinant antibody cytokine fusion proteins |
| US6027725A (en) * | 1991-11-25 | 2000-02-22 | Enzon, Inc. | Multivalent antigen-binding proteins |
| AU5670194A (en) * | 1992-11-20 | 1994-06-22 | Enzon, Inc. | Linker for linked fusion polypeptides |
| UA40577C2 (uk) * | 1993-08-02 | 2001-08-15 | Мерк Патент Гмбх | Біспецифічна молекула, що використовується для лізису пухлинних клітин, спосіб її одержання, моноклональне антитіло (варіанти), фармацевтичний препарат, фармацевтичний набір (варіанти), спосіб видалення пухлинних клітин |
| US5723125A (en) * | 1995-12-28 | 1998-03-03 | Tanox Biosystems, Inc. | Hybrid with interferon-alpha and an immunoglobulin Fc linked through a non-immunogenic peptide |
| PT1037927E (pt) | 1997-12-08 | 2004-10-29 | Emd Lexigen Res Ct Corp | Proteinas de fusao heterodimericas uteis para imunoterapia de abordagem selectiva e estimulacao imunologica geral |
| SK782002A3 (en) | 1999-07-21 | 2003-08-05 | Lexigen Pharm Corp | FC fusion proteins for enhancing the immunogenicity of protein and peptide antigens |
| US7067110B1 (en) | 1999-07-21 | 2006-06-27 | Emd Lexigen Research Center Corp. | Fc fusion proteins for enhancing the immunogenicity of protein and peptide antigens |
| BR0013231A (pt) | 1999-08-09 | 2002-07-23 | Lexigen Pharm Corp | Complexos citocina-anticorpo múltiplos |
| EP1228214A2 (de) | 1999-11-12 | 2002-08-07 | MERCK PATENT GmbH | Erythropoietinformen mit verbesserten eigenschaften |
| JP5179689B2 (ja) | 2000-02-11 | 2013-04-10 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング | 抗体ベース融合タンパク質の循環系内半減期の増強 |
| JP5390055B2 (ja) | 2000-06-29 | 2014-01-15 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング | 免疫サイトカインの取り込み増強剤との併用治療による抗体−サイトカイン融合タンパク質媒介免疫応答の増強 |
| HUP0303428A2 (hu) | 2001-03-07 | 2004-01-28 | Merck Patent Gmbh. | Expressziós eljárás hibrid izotípusú antitestcsoportot tartalmazó fehérjékhez |
| WO2002079415A2 (en) | 2001-03-30 | 2002-10-10 | Lexigen Pharmaceuticals Corp. | Reducing the immunogenicity of fusion proteins |
| KR100900166B1 (ko) | 2001-05-03 | 2009-06-02 | 메르크 파텐트 게엠베하 | 재조합 종양 특이적 항체 및 이들의 용도 |
| ATE542137T1 (de) | 2001-12-04 | 2012-02-15 | Merck Patent Gmbh | Immunocytokine mit modulierter selektivität |
| AU2003241313A1 (en) * | 2002-04-23 | 2003-11-10 | Roger Williams Hospital | Compositions and methods for stem cell delivery |
| EP1558647B1 (de) | 2002-11-08 | 2015-06-10 | Ablynx N.V. | Einzeldomaene antikörpern gegen tnf-alpha und ihre verwendungen |
| EP2284192A3 (de) | 2002-11-08 | 2011-07-20 | Ablynx N.V. | Antikörper aus Camelidae zur sublingualen Verabreichung |
| CN100432105C (zh) | 2002-12-17 | 2008-11-12 | 默克专利有限公司 | 与gd2结合的小鼠14.18抗体的人源化抗体(h14.18)以及其与il-2的融合 |
| PT1687338E (pt) | 2003-11-07 | 2011-01-20 | Ablynx Nv | Anticorpos de domínio único vhh de camelídeos direccionados para o receptor do factor de crescimento epidérmico e suas utilizações |
| PT1699822E (pt) | 2003-12-30 | 2008-07-30 | Merck Patent Gmbh | Proteínas de fusão de il-7 |
| BRPI0417916A (pt) | 2003-12-31 | 2007-04-10 | Merck Patent Gmbh | proteìna de fusão de fc-eritropoietina com farmacocinética melhorada |
| AU2005206277B2 (en) | 2004-01-22 | 2011-06-23 | Merck Patent Gmbh | Anti-cancer antibodies with reduced complement fixation |
| US7670595B2 (en) | 2004-06-28 | 2010-03-02 | Merck Patent Gmbh | Fc-interferon-beta fusion proteins |
| RU2437893C2 (ru) | 2004-12-09 | 2011-12-27 | Мерк Патент Гмбх | Варианты il-7 со сниженной иммуногенностью |
| AU2006249144B2 (en) | 2005-05-18 | 2011-11-17 | Ablynx Nv | Improved NanobodiesTM against Tumor Necrosis Factor-alpha |
| MX2007014564A (es) | 2005-05-20 | 2008-02-07 | Ablynx Nv | Anticuerpos de vhh de dominio unico contra el factor de von willebrand. |
| EP2270050B1 (de) | 2005-12-30 | 2013-06-05 | Merck Patent GmbH | Anti-C19 Antikörper mit reduzierter Immunogenizität |
| EP1966238B1 (de) | 2005-12-30 | 2012-04-25 | Merck Patent GmbH | Interleukin-12p40-varianten mit verbesserter stabilität |
| SG175233A1 (en) | 2009-04-22 | 2011-11-28 | Merck Patent Gmbh | Antibody fusion proteins with modified fcrn binding sites |
| US9340605B2 (en) | 2009-10-22 | 2016-05-17 | Universiteit Twente | VHH for application in tissue repair, organ regeneration, organ replacement and tissue engineering |
| CN116769054A (zh) | 2016-02-05 | 2023-09-19 | 奥里尼斯生物科学私人有限公司 | 双特异性信号传导剂及其用途 |
| EP4276114A3 (de) | 2016-03-07 | 2024-02-21 | Vib Vzw | Einzeldomänenantikörper gegen cd20 |
| US11753463B2 (en) | 2016-05-13 | 2023-09-12 | Orionis Biosciences BV | Therapeutic targeting of non-cellular structures |
| MX2019009255A (es) | 2017-02-06 | 2019-11-05 | Orionis Biosciences Nv | Proteínas quiméricas dirigidas y sus usos. |
| WO2019148089A1 (en) | 2018-01-26 | 2019-08-01 | Orionis Biosciences Inc. | Xcr1 binding agents and uses thereof |
| CN112074267B (zh) | 2018-02-05 | 2024-06-28 | 奥里尼斯生物科学公司股份有限公司 | 成纤维细胞结合剂及其用途 |
| JP7773372B2 (ja) | 2019-03-28 | 2025-11-19 | オリオニス バイオサイエンシズ，インコーポレイテッド | 線維芽細胞活性化タンパク質結合物質およびその使用 |
| UY38701A (es) | 2019-05-21 | 2020-12-31 | Novartis Ag | Moléculas de unión a cd19, conjugados, composiciones que las comprenden y usos de las mismas |
| CN118994397A (zh) | 2019-05-21 | 2024-11-22 | 诺华股份有限公司 | 针对bcma的三特异性结合分子及其用途 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4676980A (en) * | 1985-09-23 | 1987-06-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Target specific cross-linked heteroantibodies |
| GB8626412D0 (en) * | 1986-11-05 | 1986-12-03 | Clark M R | Antibodies |
| US4882424A (en) * | 1987-05-11 | 1989-11-21 | Dana-Farber Cancer Institute, Inc. | Activation antigen |
-
1988
- 1988-06-01 DE DE3853740T patent/DE3853740T2/de not_active Expired - Fee Related
- 1988-06-01 ES ES88108793T patent/ES2073394T3/es not_active Expired - Lifetime
- 1988-06-01 AT AT88108793T patent/ATE122238T1/de not_active IP Right Cessation
- 1988-06-01 EP EP88108793A patent/EP0294703B1/de not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| DE3853740T2 (de) | 1995-11-09 |
| EP0294703A2 (de) | 1988-12-14 |
| JPS643128A (en) | 1989-01-06 |
| EP0294703A3 (en) | 1990-06-27 |
| EP0294703B1 (de) | 1995-05-10 |
| DE3853740D1 (de) | 1995-06-14 |
| ES2073394T3 (es) | 1995-08-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE3853740D1 (de) | Bifunktionelle Antikörperkonstruktionen und Verfahren zur selektiven Tötung von Zellbeständen. | |
| DE69033705D1 (de) | Hybride immunglobuline | |
| DE69014474D1 (de) | Antikörper gegen TNF-Bindungsprotein I und deren F(ab)-Fragmente. | |
| DE69028412D1 (de) | Verfahren zum transport von molekülen in eukaryotenzellen | |
| ATE190724T1 (de) | Polymere phosphoniumsalze, die chemilumineszenzverstärkung von 1,2-dioxetanen hervorrufen, und deren verwendung. | |
| FR2624665B1 (fr) | Materiau d'etancheite electrique au milieu environnant et procede d'etancheite utilisant ce materiau | |
| DE3686433D1 (de) | Verfahren und geraet zum bewegen und herstellen von unterirdischen durchlaessen im boden. | |
| ATA163595A (de) | Hochmolekulare und niedermolekulare fraktionen des von willebrand-faktors | |
| PT85992A (de) | Verfahren zur bestimmung von anti-hiv, mittel dazu und ihre verwendung in diesem verfahren | |
| CA2011479A1 (en) | Process for the adhesive binding of paper layers | |
| DE68918823D1 (de) | Vorrichtung zum Ausschneiden von Tab-Anordnungen und zum Formen von deren Anschlüssen. | |
| PT87809A (pt) | Promotoren zur expression von freemd-dna in methylotrophen bakterien deren gewinnung und deren verwendung | |
| DE3581185D1 (de) | Neue pfropfpolymerisate und deren abmischungen mit polyamiden. | |
| DE58904672D1 (de) | Verfahren zur herstellung einer festphasenmatrix. | |
| DE69224907D1 (de) | Polyacrylamid-matrix-gel | |
| TR23834A (tr) | Parafin bakimindan zengin petrollerde ve petrol fraksiyonlarinda(i) akis duezelticisi olarak atilik ve/ veya metakrilik asit esterlerinin seckin...... | |
| EP0374946A3 (de) | Verfahren zum Nachweis von kohlenhydrathaltigen Verbindungen | |
| DE68917944D1 (de) | O.R.I.-gehemmte Motorbrennstoffzusammensetzung, und einlagerungsbeständiges Konzentrat. | |
| DE58906771D1 (de) | Neue Copolymere, deren Mischungen mit Poly(meth)acrylsäureestern und deren Verwendung zur Verbesserung der Fliessfähigkeit von Rohölen in der Kälte. | |
| IT1229123B (it) | Tracciante per prodotti petroliferi | |
| DE3883696D1 (de) | Anti-Krebs-Mittel und Reagenz zur Gewinnung von Revertanten. | |
| DE3569828D1 (en) | Method for immobilizing substances in synthetic solid phases, and synthetic solid phases for use in immunosorbent assays | |
| ATE98997T1 (de) | Aus nukleinsaeuren von menschlichen papillomaviren bestehende hybridisierungsproben und methoden fuer deren anwendung. | |
| DE68907243D1 (de) | Antriebsvorrichtung zum nacheinander in betriebnehmen von lasten. | |
| KR860008779A (ko) | 항체 형성 화합물의 제조방법 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification | ||
| REN | Ceased due to non-payment of the annual fee |